gsk news - Search News

GSK, Pfizer RSV vaccine sales fall in US

Analysis-GSK, Pfizer RSV vaccine sales fall in US as millions fewer people line up

U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and said it was a once-in-a-lifetime shot for now, excluding millions of people who got one last year.

BioPharma Dive · 19h

GSK says RSV vaccine protects against disease over three seasons

Cumulatively, data showed the shot to be 63% effective across the three-year period. However, efficacy appeared to wane and GSK said it expects revaccination will eventually be needed.

Seeking Alpha · 1d

U.K. court rules in Pfizer's favor in GSK RSV vaccine dispute: report

Pfizer (PFE) has reportedly succeeded in getting a U.K. court to invalidate two of GSK’s (GSK) patents for its RSV vaccine. Read more here.

Reuters on MSN · 2d

Pfizer wins bid to invalidate GSK's patents over RSV vaccine

Pfizer on Monday won a bid in a London court to invalidate two of GSK's patents relating to a respiratory syncytial virus (RSV) vaccine. The two pharmaceutical giants are among a number of companies in competition for a vaccine for RSV,

22hon MSN

GSK RSV shot 43% effective against severe disease in third year

GSK said on Tuesday that its Arexvy respiratory syncytial virus vaccine was 43.3% effective in preventing severe illness in ...

GlaxoSmithKline (GSK) Receives a Hold from Goldman Sachs

In a report released today, Rajan Sharma from Goldman Sachs maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a ...

FiercePharma20h

GSK touts 3-year data on RSV shot Arexvy after CDC's narrower usage recommendation

While recent CDC guidance threatens to shrink the market for a new class of immunizations, GSK continues to build the case ...

Pharmabiz3h

GSK presents positive data from AReSVi-006 phase III trial of respiratory syncytial virus vaccine, Arexvy at CHEST 2024 annual meeting

GSK presents positive data from AReSVi-006 phase III trial of respiratory syncytial virus vaccine, Arexvy at CHEST 2024 annual meeting: London, UK Wednesday, October 9, 2024, 14:0 ...

GSK Presents Positive Data for AREXVY, Its Respiratory Syncytial Virus (RSV) Vaccine, Indicating Protection Over Three RSV Seasons

GSK presents positive data for AREXVY, its respiratory syncytial virus (RSV) vaccine, indicating protection over three RSV ...

22h

GSK Announces Positive Data From AReSVi-006 Phase III Trial For RSV Vaccine Arexvy

GSK plc (GSK, GSK.L) announced Tuesday new data from the AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial evaluating ...

Sanofi, GSK, CSL tapped to expand US bird flu vaccine supply

GSK , Sanofi and CSL Ltd have secured $72 million from the U.S. government to ramp up production of bird flu vaccines, a ...

Pfizer Wins London Court Battle, GSK's Respiratory Syncytial Virus Vaccine Patents Invalidated

On Monday, Pfizer Inc. (NYSE:PFE) stock is trading higher with a session volume of 31.16 million as per data from Benzinga ...

13d

GSK CEO Is Trying to Move Past Zantac ‘Overhang’ on Shares

GSK Plc CEO Emma Walmsley doesn’t want the company’s employees spending any time thinking about the ongoing litigation over ...

BioSpace2d

TIGITs Trend Upward After iTeos/GSK Present Positive Data at ESMO

After several high-profile failures, including BMS’ $1.5B breakup with Agenus, anti-TIGIT therapies are generating cautious ...

GSK Pharma to expand into oncology, focus on adult vaccines in India

GlaxoSmithKline Pharma is shifting focus to specialty treatments and preventive healthcare, emphasizing adult vaccines and ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

Related topics